Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome

• Shiratori, Souichi

• Fujimoto, Katsuya

• Nishimura, Machiko

• Hatanaka, Kanako C.

• Kosugi-Kanaya, Mizuha

• Okada, Kohei

• Sugita, Junichi

• Shigematsu, Akio

• Hashimoto, Daigo

• Endo, Tomoyuki

• Kondo, Takeshi

• Abe, Riichiro

• Hashino, Satoshi

• Matsuno, Yoshihiro

• Shimizu, Hiroshi

• Teshima, Takanori

Bibliographic Information

Other Title

• RIC-HSCT for MF/SS

Abstract

Advanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS. With a median follow-up period of 954days after HSCT, the estimated 3-year overall survival was 85.7% (95% confidence interval, 33.4-97.9%) with no non-relapse mortality. Five patients relapsed after RIC-HSCT; however, in four patients whose relapse was detected only from the skin, persistent complete response was achieved in one patient, and the disease was manageable in other three patients by the tapering of immunosuppressants and donor lymphocyte infusion, suggesting that graft-versus-lymphoma effect and "down-staging" effect from advanced stage to early stage by HSCT improve the prognosis of advanced-stage MF/SS. These results suggest that RIC-HSCT is an effective treatment for advanced MF/SS.

Journal

• Hematological oncology

  Hematological oncology 34 (1), 9-16, 2016-03

  Wiley

Keywords

• mycosis fungoides
• Sezary syndrome
• allogeneic hematopoietic stem cell transplantation
• reduced-intensity conditioning
• graft-versus-lymphoma effect

Details

• CRID: 1050001339020449408
• NII Article ID: 120005981361
• HANDLE: 2115/64629
• ISSN: 02780232
• Text Lang: en
• Article Type: journal article
• Data Source:
  • IRDB
  • CiNii Articles